1. Home /
  2. Pharmaceuticals

Pharmaceuticals

Johnson & Johnson Is in the News, but How Do the Charts Look?

Johnson & Johnson Is in the News, but How Do the Charts Look?

I am not focused on today's price movement of the stock but the pattern from the end of 2017.

J&J Ordered to Pay $572 Million in Oklahoma Opioid Case

J&J Ordered to Pay $572 Million in Oklahoma Opioid Case

J&J said it would appeal the judge's decision. The judgment was less than Wall Street was expecting. The stock rose after hours.

How Abbott Is Celebrating Women in STEM on Women's Equality Day

How Abbott Is Celebrating Women in STEM on Women's Equality Day

Here's how to empower the next generation of women going into STEM.

How Reinventing the Lab Coat Can Empower the Minds of Tomorrow

How Reinventing the Lab Coat Can Empower the Minds of Tomorrow

Here's how a project--such as reinventing the lab coat--can empower the minds of tomorrow.

Medicines Co. Rises on Positive Phase 3 Trial for Cholesterol Lowering Therapy

Medicines Co. Rises on Positive Phase 3 Trial for Cholesterol Lowering Therapy

The biopharmaceutical company reports positive Phase 3 trial results for its cholesterol-lowering therapy inclisiran.

Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Jim Cramer breaks down Amgen's deal to buy Otezla's rights from Celgene.

Why Actions Speak Louder Than Words When It Comes to Equality

Why Actions Speak Louder Than Words When It Comes to Equality

Equality in the workplace matters.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.